Bristol Myers Squibb’s Opdivo plus Yervoy Dual Immunotherapy Receives First-in-Class Approval in China for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
Source: The Paper
Colorectal cancer (CRC) is a malignant tumor that occurs in the colon or rectum, both of which are parts of the human digestive system. The dMMR phenotype occurs when proteins responsible for repairing mismatch errors during DNA replication are missing or lose function, leading to MSI-H tumors. Public data shows that approximately 5% to 7% of patients with metastatic colorectal cancer have dMMR or MSI-H tumors. These patients are less likely to benefit from traditional chemotherapy and generally have a poorer prognosis.
Ipilimumab is a CTLA-4 antibody, and nivolumab is a PD-1 inhibitor.In March 2024, the dual immunotherapy combination was included by the CDE as a breakthrough treatment. In the same month, the dual immunotherapy combination was also granted priority review by the CDE forFirst-line treatment for colorectal cancer. This is precisely the indication for which this combination therapy was approved this time.
Disclaimer:
The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance regarding the statements and viewpoints presented, and does not provide any express or implied guarantees concerning the accuracy, reliability, or completeness of the content. Readers are advised to use the information solely as a reference and assume full responsibility for their actions. The various articles published by this official account focus on sharing; if there is any infringement, please contact us, and we will delete the content.
ICGT 2025
Booths are booking up fast!
Scan to consult immediately
Phone: 13816031174
(Same as WeChat)
Sponsorship forms include but are not limited toSpeaking slots, exhibition booths, color pages in the conference proceedings, dinner sponsorship, promotional conference materials, etc.